<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03352726</url>
  </required_header>
  <id_info>
    <org_study_id>BIOPOT</org_study_id>
    <nct_id>NCT03352726</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects</brief_title>
  <acronym>V712-103</acronym>
  <official_title>An Open-label Phase I Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DBV Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DBV Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to assess the biological potency of the In-House Reference Preparation (IHRP)
      of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biological potency of the In-House Reference peanut proteins extract (DBV712-IHRP) in arbitrary Biological Units (BU)</measure>
    <time_frame>1 day to 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs), Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs)</measure>
    <time_frame>Throughout the study (1 day to 2 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>DBV712 Solution for Skin Prick Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DBV712 In-House Reference Skin Prick Test preparation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DBV712 IHRP</intervention_name>
    <description>DBV712 Solution for Skin Prick Test</description>
    <arm_group_label>DBV712 Solution for Skin Prick Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Male or female subjects aged between 12-50 years

          -  Physician-diagnosed peanut allergy

          -  Subject currently following a strict peanut-free diet

          -  Documented history of positive test to peanut-specific IgE (ImmunoCAP system) &gt;0.7
             kU/L

          -  Positive peanut SPT with a largest wheal diameter â‰¥ 8 mm

        Main Exclusion Criteria:

          -  Uncontrolled asthma

          -  Peanut allergen immunotherapy whatever the route, either ongoing or previously started
             and having lasted more than one month (&gt;30 days)

          -  Topical use of steroids within the past 14 days prior to the Screening SPT

          -  Inability to discontinue short-acting antihistamines

          -  Atopic dermatitis, eczema or urticaria on the areas to be tested
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perry, MD</last_name>
      <phone>501-364-1060</phone>
      <email>PerryTamaraT@uams.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greenhawt, MD</last_name>
      <phone>720-777-2575</phone>
      <email>Matthew.Greenhawt@childrenscolorado.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EPIT</keyword>
  <keyword>Epicutaneous</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Viaskin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

